IL314070A - Macrocyclic compounds and use as kinase inhibitors - Google Patents
Macrocyclic compounds and use as kinase inhibitorsInfo
- Publication number
- IL314070A IL314070A IL314070A IL31407024A IL314070A IL 314070 A IL314070 A IL 314070A IL 314070 A IL314070 A IL 314070A IL 31407024 A IL31407024 A IL 31407024A IL 314070 A IL314070 A IL 314070A
- Authority
- IL
- Israel
- Prior art keywords
- nrerf
- alkyl
- methyl
- mmol
- 2nrerf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296705P | 2022-01-05 | 2022-01-05 | |
| US202263435654P | 2022-12-28 | 2022-12-28 | |
| PCT/US2023/060039 WO2023133375A1 (en) | 2022-01-05 | 2023-01-03 | Macrocyclic compounds and use as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314070A true IL314070A (en) | 2024-09-01 |
Family
ID=87074235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314070A IL314070A (en) | 2022-01-05 | 2023-01-03 | Macrocyclic compounds and use as kinase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250074920A1 (https=) |
| EP (1) | EP4460498A4 (https=) |
| JP (1) | JP2025503592A (https=) |
| KR (1) | KR20240131416A (https=) |
| AU (1) | AU2023204770A1 (https=) |
| CA (1) | CA3246487A1 (https=) |
| IL (1) | IL314070A (https=) |
| MX (1) | MX2024008413A (https=) |
| TW (1) | TW202334168A (https=) |
| WO (1) | WO2023133375A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024266587A1 (en) * | 2023-05-02 | 2025-09-11 | Blossomhill Therapeutics, Inc. | Egfr inhibitors for treating disease |
| WO2025212729A1 (en) * | 2024-04-03 | 2025-10-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03376B (me) * | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| US20160031888A1 (en) * | 2013-03-13 | 2016-02-04 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| TWI707852B (zh) * | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| EP4178958A4 (en) * | 2020-07-10 | 2024-12-11 | Blossomhill Therapeutics, Inc. | MACROCYCLES AND THEIR USE |
-
2023
- 2023-01-03 AU AU2023204770A patent/AU2023204770A1/en active Pending
- 2023-01-03 WO PCT/US2023/060039 patent/WO2023133375A1/en not_active Ceased
- 2023-01-03 MX MX2024008413A patent/MX2024008413A/es unknown
- 2023-01-03 KR KR1020247025807A patent/KR20240131416A/ko active Pending
- 2023-01-03 CA CA3246487A patent/CA3246487A1/en active Pending
- 2023-01-03 JP JP2024540747A patent/JP2025503592A/ja active Pending
- 2023-01-03 EP EP23737695.9A patent/EP4460498A4/en active Pending
- 2023-01-03 US US18/725,951 patent/US20250074920A1/en active Pending
- 2023-01-03 IL IL314070A patent/IL314070A/en unknown
- 2023-01-05 TW TW112100378A patent/TW202334168A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3246487A1 (en) | 2023-07-13 |
| MX2024008413A (es) | 2024-09-17 |
| US20250074920A1 (en) | 2025-03-06 |
| TW202334168A (zh) | 2023-09-01 |
| EP4460498A1 (en) | 2024-11-13 |
| EP4460498A4 (en) | 2026-03-25 |
| JP2025503592A (ja) | 2025-02-04 |
| AU2023204770A1 (en) | 2024-07-18 |
| KR20240131416A (ko) | 2024-08-30 |
| WO2023133375A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404281B2 (en) | Diaryl macrocycles as modulators of protein kinases | |
| JP7644517B2 (ja) | Ｋｒａｓ突然変異型タンパク質阻害剤 | |
| US11008337B2 (en) | Chiral diaryl macrocycles as modulators of protein kinases | |
| WO2021249563A1 (zh) | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 | |
| WO2019134539A1 (zh) | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 | |
| WO2015058661A1 (zh) | Bcr-abl激酶抑制剂及其应用 | |
| IL314070A (en) | Macrocyclic compounds and use as kinase inhibitors | |
| WO2023240140A1 (en) | Indazole macrocycles and their use | |
| WO2024012425A1 (zh) | 作为ripk1抑制剂的杂环化合物 | |
| JP2025530793A (ja) | Ｅｇｆｒ阻害剤及びその使用 | |
| TWI652265B (zh) | 氮雜吲哚衍生物 | |
| TW202245760A (zh) | 大環化合物及其用途 | |
| WO2025010294A2 (en) | Macrocyclic compounds and use as tyk2 inhibitors | |
| CN118946559A (zh) | 大环化合物及其作为激酶抑制剂的用途 | |
| HK40119440A (zh) | 大环化合物及其作为激酶抑制剂的用途 |